{"schema_version":"secwatch.filing_event.v1","accession":"0001672688-26-000118","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2026-06-24T10:32:11+00:00","discovered_at":"2026-06-24T10:35:00.283520+00:00","generated_at":"2026-06-24T10:35:09.367709+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Absci reports positive interim Phase 1 data for ABS-201; half-life ≥65 days supports dosing 2-3 times/6 months","bullets":["No serious adverse events; TEAEs were mild except one moderate headache deemed unrelated to treatment.","Estimated half-life of at least 65 days across all four SAD cohorts (150–1800 mg IV).","MAD portion in androgenetic alopecia participants initiated; interim PoC data expected H2 2026.","Phase 2 trial for endometriosis planned later this year.","32 healthy volunteers enrolled in four SAD cohorts; data cutoff June 8, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001672688-26-000118","json":"https://secwatch.observer/filing/0001672688-26-000118.json","markdown":"https://secwatch.observer/filing/0001672688-26-000118.md","text":"https://secwatch.observer/filing/0001672688-26-000118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/0001672688-26-000118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/absc-20260624.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T10:35:09.367709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}